Introduction
In the last few years, we have seen advances in hepatitis C drug development that rival those for any other disease in medical history. We are now able to cure hepatitis C virus (HCV) infection in most patients with highly effective, safe and tolerable combinations of oral direct-acting antivirals (DAAs) taken for 8-24 weeks. Eradication of hepatitis C is being discussed for the first time, although actual implementation will be challenging even in high-income countries such as the United States (Edlin and Winkelstein, 2014) . In recognition of this rapid evolution in HCV drug development, the World Health Organization (WHO) issued its first guidelines addressing HCV treatment in 2014 (http:// apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng. pdf).
These guidelines acknowledge the many barriers to implementation in low-and middle-income countries (LMIC). However, the most profound barrier to accessing treatment for hepatitis C globally, including in high-income countries, is the exorbitant prices of new DAAs (over US$100,000 per treatment course in the United States). We have learned important lessons about how to ensure that HIV-infected patients from LMIC do not die unnecessarily from eminently treatable infections. It is no longer a radical proposal that governmental and nongovernmental agencies commit to the provision of life-long treatment and care of people living with HIV across the globe. We have the opportunity to translate even more rapid advances in HCV drug development into the global eradication of this disease. This will depend on our ability to match the level of public-private partnerships that have transformed control of other global diseases. This paper will examine some of the unmet medical needs in LMIC that would have to be achieved to eliminate premature deaths due to complications of hepatitis C.
An estimated 185 million people have been infected with HCV, and over 80% live in LMICs (Mohd Hanafiah et al., 2013) . Untreated HCV infection leads to liver cirrhosis in up to a third of those who are chronically infected and these individuals are at risk for complications such as hepatocellular carcinoma (HCC) and hepatic decompensation (Davis et al., 2010) . Up to 500,000 people die each year from complications secondary to HCV infection; most in LMIC (Lozano et al., 2012) .
Eradicating infection with hepatitis C is the most effective way to reduce the incidence of liver decompensation and hepatocellular carcinoma (HCC) (van der Meer et al., 2012) . According to the US Centers for Disease Control and Prevention (CDC), one premature death is prevented for every three virological cures (Rein et al., 2012). Few medical interventions against chronic diseases can match this number-needed-to-treat rate. In addition, reducing the pool of infected people could significantly decrease new infections and the overall prevalence of HCV infection in a community (Martin et al., 2013b) . Major challenges include diagnosing infected individuals, linking them into care and ensuring access to treatment with DAAs.
Who has HCV infection?
In high-income countries, HCV spread extensively in the 1940's and 1950's (Japan) through the 1960's to 1980's (North America and Western Europe) via contaminated blood supplies, poor infection-control practices during medical procedures, and injection drug use, as well as other, less well defined risks of community acquisition (Nakano et al., 2004) . Because of changes in injection drug use and infection control practices with the advent of the HIV epidemic and blood supply screening, HCV transmission has significantly decreased over the last 20 years in high-income regions (Armstrong et al., 2006) .
Low-and middle-income countries often have ongoing routes of infection. Formal and informal medical care using unsafe injections or improperly sterilized medical equipment account for 40% of global HCV infections (Hauri et al., 2004; Averhoff et al., 2012) . In addition, the WHO has found that 20% of surveyed countries do not screen their blood supply for HCV.
With the exception of a few countries such as France, which have instituted national viral hepatitis testing programs, accuracy of the estimates of anti-HCV antibody prevalence in most regions of the world is poor (Delarocque-Astagneau et al., 2010) . In the US, for example, estimates of the numbers of infected individuals range from 3.2 million to over 6 million (Edlin, 2011; Holmberg et al., 2013b) . Many regional prevalence studies tested blood donors or pregnant women, neither of whom may be representative of the broader population of individual countries (Mohd Hanafiah et al., 2013) . A recent meta-analysis of global HCV seroprevalence that used data from general population surveys estimated that there are >180 million people with anti-HCV antibodies, and over 100 million are in South and East Asia (Mohd Hanafiah et al., 2013) . This study also highlighted regions with very limited seroprevalence data, including the Caribbean, Central Asia, Andean Latin America, and Central Sub-Saharan Africa. Surveys of immigrant populations in high-income countries are consistent with a high prevalence of anti-HCV antibodies and complications of infection in LMIC. For example, a survey of Somali versus non-Somali patients at a clinic in Minnesota, USA found anti-HCV antibody prevalence rates of 9.9% and 6.6% in Somali men and women, respectively, compared to rates of 3.2% and 1.7% in non-Somali male and female patients as well as high rates of HCV-associated HCC in Somalis (Shire et al., 2012) .
Risk-based testing performs poorly as a strategy to identify people who have been exposed to HCV, as evidenced by up to 85% of people in the United States who are unaware of their diagnosis in spite of recommendations in place since 1998 to test people with well characterized risk factors (Mitchell et al., 2010; Smith et al., 2012) . This is likely due to stigma around certain risk behaviors such as injection drug use and lack of knowledge about the risk of certain exposures, such as receipt of blood products years ago or exposure to medical procedures prior to effective infection control practices. The United States recently recognized that 75% of people with HCV infection were born from 1945 through 1965 because of the dynamics of peak transmission during the 1960's to 1980's ). This has led to a recommendation to test everyone in this birth cohort once. Interestingly, similar age-specific peaks in seroprevalence of anti-HCV antibodies among the 55-64 years age group are seen across the globe (Mohd Hanafiah et al., 2013) .
Progression to advanced fibrosis is a function of duration of HCV infection and current age, as well as factors that accelerate fibrosis such as excessive alcohol consumption and HIV coinfection. Men tend to have higher infection rates and lower rates of spontaneous clearance of acute infection, leading to a disproportionate burden of advanced liver disease (it is estimated that 75% of the people in the US with HCV infection and cirrhosis are men) (Davis et al., 2010) . To identify those most at risk for development of severe complications of HCV infection, a global age-based HCV testing program, adjusted for local epidemiology, would be a first step to identifying those people with more advanced liver disease who are most likely to benefit immediately from diagnosis and treatment.
What new diagnostic methods are needed for hepatitis C?
Most screening programs use an enzyme-linked immunoassay to identify antibodies against HCV. The costs of these tests range from US$10 to $25. Low-income countries are able to access lower cost anti-HCV antibody tests, but there is little quality control or assurance about test performance in specific countries. The WHO hepatitis C guidelines suggest that countries that attribute much of their HCV transmission to health-care settings may need to consider screening the general population, which would require access to high quality, inexpensive tests. Ideally, the costs for serological tests should be similar to HIV serological tests, which are less than US$ 1 per assay in low-income countries, since the total number of people requiring testing for anti-HCV could approach 2 billion (Wu and Zaman, 2012) .
Fifteen to thirty percent of exposed persons will spontaneously clear their acute HCV infection, so all persons with detected anti-HCV antibodies need to undergo further testing to determine the presence of virus and active infection. Examples of confirmatory tests include qualitative and quantitative HCV nucleic acid testing (NAT) and core antigen detection assays. Unfortunately, confirmation of active HCV infection was only performed about 50% of the time in a CDC survey of US cities and confirmation is much lower in many LMIC (Centers for Disease and Prevention, 2013) . There are substantial barriers to widespread implementation of NAT in LMIC, including the requirement for rapid processing of whole blood, cold storage of samples, expensive instruments and reagents, trained technicians, and expense of the assays.
In certain countries of sub-Saharan Africa, there is an important additional complexity. A relatively high percent of persons are anti-HCV positive, yet HCV RNA negative. Table 1 provides an overview of recent studies that compared anti-HCV antibody prevalence with confirmed NAT testing in sub-Saharan Africa. Supplemental Table 1 has a more complete listing of studies and includes results of quantitative HCV RNA testing. Few studies have reported quantitative HCV RNA results, making it difficult to determine the level of sensitivity future assays would require for detection of active HCV infection. The phenomenon of high rates of false positive anti-HCV serological tests is true both for patients with HCV mono-infection and HIV/HCV coinfection, and may be related to cross-reactivity with endemic infectious agents. These findings have substantial implications. Since serological rapid diagnostics tests are less expensive than NAT, these are often used to screen prospective blood donors, which can result in inappropriate exclusion of uninfected donors in a region that already has the lowest per-population rate of blood donation and the highest wastage of donated units due to transmittable infectious diseases. (see the 2013 WHO Global Report on blood safety for additional details: http://www.who.int/bloodsafety/transfusion_services/WHO_ 
Survey of recent studies that measured both hepatitis C seroprevalence and confirmation of active infection with a nucleic-acid test in sub-Saharan Africa. The percentage of individuals in sub-Saharan Africa who have active infection confirmed by detection of HCV RNA after sero-reactive anti-HCV antibody tests is much lower than in other parts of the world. It is unclear whether these results represent immunological cross-reactivity with other immunogens that are common in this region. The lack of specificity poses challenges for affordable HCV screening programs in sub-Saharan Africa. Abbreviations used: HCV = hepatitis C virus; NAT = nucleic acid testing; PCR = polymerase chain reaction; EIA = enzyme immunoassay; RSA = rapid strip assay.
GlobalStatusReportSelf-SufficiencyinBloodBloodProducts.pdf?ua= 1). Patients may have management decisions made about their care without having true infection. Or, patients may progress to advanced liver disease, because they were not tested due to mistrust in the results of available assays.
Globally, access to HCV NAT or direct viral antigen detection is essential. Diagnostic companies should take up the challenge of developing rapid, point-of-care assays for the detection of active HCV infection in individuals that are in the price range of HIV viral load or p24 antigen tests in low-income countries. Preferably, these assays will require minimal sample processing and allow performance at room temperature. The academic community in these countries can help define how sensitive these assays need to be, since there may be a balance between sensitivity and cost. A qualitative assay that can detect the equivalent of at least 1000 IU/mL HCV RNA may be sufficient for most management purposes and participants in a collaboration organized by the Foundation for Innovative New Diagnostics and the Forum for Collaborative HIV Research have started work on a diagnostic target product profile (November 11, 2014) . Ultimately, a single qualitative assay that directly detects the presence of HCV could be used to diagnose active infection and confirm cure after antiviral treatment since the additional information from a quantitative HCV RNA value will likely not impact any clinical management decisions in the era of DAAs.
Global agencies and foundations should encourage and support development of low-cost, point-of-care, polyvalent platforms that can perform direct viral testing for HCV as well as HIV and hepatitis B virus (HBV), since co-infection with these viruses is common in many regions of the world. Cross-platform testing capacity would minimize the possibility that resource-limited settings would have to invest in multiple analyzer platforms or be forced to choose which infections to diagnose.
Staging liver disease
As treatments improve, the distinction between stage 0 and stage 1 or 2 liver fibrosis will have little impact on patient management. However, it will be important to distinguish mild to moderate fibrosis from advanced fibrosis (bridging fibrosis or cirrhosis). Those with advanced fibrosis are more likely to develop complications in the near future, which drive urgency to treat as well as the need for disease management interventions such as screening for HCC. There are a number of non-invasive fibrosis markers that use commonly acquired laboratory values and patient characteristics to calculate scores. The United States Preventive Services Task Force performed an extensive review of scoring systems and found that the age-platelet index and APRI (which uses AST and platelets) were moderately useful for diagnosing cirrhosis (Chou and Wasson, 2013) . FIB-4 (which uses ALT, AST, age and platelet count) also has a high correlation with liver fibrosis stage by biopsy (Holmberg et al., 2013a) . These serum biomarker panels are relatively inexpensive and can be repeated annually to detect liver fibrosis progression and determine who needs additional management of cirrhosis.
Eliminate ongoing HCV transmission
Of the estimated 3-4 million annual new cases of HCV infection each year, unsafe healthcare practices, such as unscreened blood products or reused syringes, account for over 2 million of these infections (Maheshwari et al., 2008) . At a minimum, LMIC need support to eliminate healthcare-associated HCV transmission. Inexpensive diagnostic tests to determine the presence of HCV RNA are needed to screen the blood supply in every country. The sensitivity of NAT for ensuring the lack of infectivity of the blood supply will be lower than that needed for clinical management, but this setting may be more amendable to higher-volume approaches like pooling samples. There should be separate regulatory pathways for evaluation of HCV diagnostics for clinical management and screening of blood products.
A modeling study in India found that the fraction of HCV infections attributed to unsafe medical injections was 38% (Reid, 2012) . In this study, universal use of auto-disposable syringes was found to be a cost-effective alternative to reused syringes. Studies such as this may help stimulate needed public-private investment in health care infrastructure to minimize avoidable iatrogenic transmission risks.
Inadequate access to sterile injection equipment, criminalization and other barriers are driving the HCV epidemic among people who inject drugs (PWID). Most ongoing HCV transmission in highand middle-income countries, and some in low-income countries is attributed to injection drug use with unsterilized equipment (Grebely and Dore, 2014) . Martin and colleagues have performed elegant analyses demonstrating that treating a small proportion of PWID in combination with high-coverage needle and syringe exchange programs and opioid substitution treatment can decrease the population level prevalence rate of HCV (Martin et al., 2013a,b) . Harm reduction interventions are also needed for primary prevention, to reduce the incidence of reinfection, and to maintain the benefits of antiviral treatment. These approaches will require a global acknowledgment of human rights for PWID, their involvement in program design, implementation and oversight, and government-level support of harm reduction and medical intervention programs.
Many PWID will enter prisons and other detention facilities at some point, creating risks for ongoing transmission to other detainees as well as opportunities for prevention and treatment. A recent meta-analysis estimated that 2.2 million detainees (26% of general detainees) globally are anti-HCV antibody positive, with over half in North America and East and Southeast Asia (Larney et al., 2013) . Global eradication of hepatitis C will require a human rights-based, logical approach to prevention, diagnosis and treatment in these detained populations.
A vaccine strategy for the prevention of hepatitis C in high-risk populations including PWID may ultimately be the most effective means of eliminating incident HCV infections. The technical challenges associated with developing an effective vaccine against a virus with such sequence variation are daunting, although an initial HCV vaccine trial has been initiated (Cox and Thomas, 2013; Drummer, 2014) .
Applying lessons from HIV to access for antiviral medications against HCV
In the last decade, multiple interventions have increased access to life-saving antiretroviral treatment (ART) for suppression of HIV. The number of individuals on ART has dramatically increased in LMIC and it is estimated that nearly 10 million people are receiving ART for as little as $100 per person annually (Jayasekera et al., 2014) . This effort represents a commitment from the world community to provide life-long treatment. We can learn lessons from interventions that have worked well, and areas that still need improvement in order to accelerate access to drugs against hepatitis C in LMIC. An excellent analysis of access to HIV, TB and HCV drugs in resource-limited settings was published by the Treatment Action Group and HIV i-Base (see Table 2 : resources for understanding hepatitis C treatment access). These authors note that access to affordable ART for HIV infection began with the mobilization of civil society to demand a human rights-based approach to treatment access. Inter-governmental agencies and foundations such as The Global Fund to Fight AIDS, Tuberculosis and Malaria, The Clinton Health Access Initiative, the United States President's Emergency Plan for AIDS Relief, and UNITAID began market shaping, pooling demand and large-scale purchase of ART and diagnostics as well as funding for the delivery of care. Additional mechanisms have been used to increase the affordability of HIV medications, including generic competition, voluntary licensing, tiered pricing, and the Medicines Patent Pool. Some governments have used TRIPS (trade-related aspects of intellectual property rights) flexibilities to increase access to affordable ART via generic production of patented medications. Regulatory approval in LMIC has been expedited by broadening the tentative approval system of the US Food and Drug Administration, continuing the WHO Prequalification Program, and expanding the European Medicines Agency's use of article 58 (a program which allows the EMA to provide a scientific opinion on certain vaccines and drugs intended for markets outside of the European Union) to help encourage regulatory modernization and minimize unnecessary duplication of efforts (see Table 2 for resources addressing access to HCV treatment using strategies that have been successful in HIV).
There are many benefits to identifying people who are infected with HCV including counseling around reducing or eliminating alcohol consumption, identifying who has cirrhosis and initiating screening for HCC and gastroesophageal varices, providing vaccinations for hepatitis A and B in those not previously exposed, and providing harm reduction counseling that may decrease the risk of HCV reinfection and transmission to others. However, the most significant way to reduce the incidence of diseases associated with HCV infection is to achieve virological cure.
In recognition that treatment is a necessary component of any eradication strategy, the WHO added pegylated interferon alfa (Peg-IFN) to the list of essential medications in 2013. However, Peg-IFN is unequivocally less effective, more toxic and difficult to administer than the DAAs. One of the ethical challenges in ART delivery in LMIC has been the use of more toxic antiretroviral agents long after they ceased being used in high-income countries. Forcing LMIC to use interferon-base therapy while high-income countries have transitioned to all-oral regimens repeats this same mistake. It is now possible for all countries to leap-frog the interferon era and go directly to DAA-based treatment.
Agreements that will result in at least a 100-fold reduction in the US price of some DAAs are already being announced. Egypt, which has the highest prevalence of HCV infection in the world, has negotiated access to sofosbuvir at a cost of US$900 for 12 weeks (http://www.reuters.com/article/2014/03/21/ushepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321; accessed 7/10/14). In September 2014, Gilead announced licensing agreements with seven Indian companies to manufacture generic hepatitis C medicines for 91 developing countries, tiered pricing in developing countries as well as differential pricing for public and private markets (http://www.gilead.com/~/media/Files/pdfs/ other/HCVGenericAgreementFactSheet.pdf). Bristol-Myers Squibb has announced plans to work with licensed generic manufacturers to supply licensed versions of daclatasvir in 90 developing countries (http://www.bms.com/responsibility/access-to-medicines/ Pages/HCV-developing-world-strategy.aspx). It remains to be seen whether generic competition will lower DAA prices to affordable levels in each of these countries, and in both public and private markets. In the excluded middle-income countries -home to millions of people with hepatitis C -no generics will be available, and prices will be set by pharmaceutical companies; widespread affordability is unlikely.
Mounting a response to epidemics in middle-income countries is complicated by the perception that MIC -as opposed to World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf HIV i-Base and Treatment Action Group 2013 PIPELINE REPORT: HIV, hepatitis C virus (HCV), and tuberculosis (TB) drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development. http://www.pipelinereport.org World-wide web resources that were used to prepare this review are listed here. These resources address access to antiretroviral medications for HIV, tuberculosis and/or hepatitis C medications in low-and middle-income countries. We can apply successful models of care and treatment access strategies for HIV or tuberculosis infections to hepatitis C management in LMIC.
low-income countries-are emerging markets for pharmaceutical products at premium pricing. In actuality, the ''bottom billion'' -960 million, or 72% of the world's poorest people, defined as less than US$1.25 per capita/day -live in MICs (http://www.ids.ac. uk/files/dmfile/Wp349.pdf). Access to health care and medicines varies widely across MICs and up to 90% of patients in MIC pay for medications out of pocket. Some countries have insurance schemes, but these do not always cover HCV treatment, diagnostic tests, or monitoring. Tiered pricing -selling medicines at different prices to improve access while generating revenue for the pharmaceutical industry -is unlikely to address treatment access in MICs. The criteria for tiered pricing is based solely on per capita gross national income (GNI) from the World Bank, leaving poor and uninsured people in MICs without access to affordable medicines (Moon et al., 2011) . Ultimately, all countries must have affordable drug pricing across the population if they are to provide treatment for HCV infection. The actual production costs for a 12-weeks DAA regimen is estimated at less than US$250, so this should be an achievable goal (Hill et al., 2014 ) (see Table 2 ). The only economic value gained from treating HCV infection is if virological cure is achieved, with potential reduction in future costs of HCV-related complication. There is no evidence that unsuccessful therapy is of any benefit to patients (Di Bisceglie et al., 2008) . It is helpful to analyze total costs per cure, which takes into account all the costs associated with treating HCV infection with a specific regimen as well as the cure rate. For example, treatment costs can include the price paid for each component of a combination regimen as well as laboratory monitoring, clinic visits, medications used to manage adverse events, hospitalizations related to treatment complications, and quality of life impact. Regimens that have higher drug prices but require less monitoring and have higher cure rates may have a lower cost per cure.
Government funded medication programs will need coordination between advocates, academic centers and health policy agencies to prioritize hepatitis C diagnosis and treatment strategies. Countries should determine the prevalence of HCV seropositivity, active infection (using HCV NAT or core antigen testing), rates of advanced liver disease complications and hepatitis C-related mortality, and costs associated with HCV infection in their population.
An example of a model that used a country-specific willingnessto-pay threshold to determine the cost effectiveness of birth cohort screening for HCV was performed by the CDC . These analyses showed that in the US, screening the 1945-1965 birth cohort was as cost effective as a number of other interventions that have been determined to be cost effective, such as hypertension or cervical cancer screening. Alternatively, a model that starts with a product's public health benefit, cost-benefit ratio and cost off-sets to derive a price that represents the value of a drug or regimen in a specific country may be a more objective way to ensure affordability (Lopert et al., 2002) . High-income countries such as the United Kingdom, Canada, and Australia use similar methodologies for determining national prices and should share models so consistent national data are collected among countries.
Choosing an antiviral treatment regimen and determining the duration of treatment has been dependent on HCV genotype with Peg-IFN + RBV, the first generation protease inhibitors, and some of the all-oral regimens in development. However, regimens that can be broadly used in LMIC should be pan-genotypic. We already have an example of a pan-genotypic regimen, the combination of sofosbuvir and the NS5a inhibitor, daclatasvir (Wang et al., 2014) . This combination is currently being studied in genotypes 1, 2, 3, 4, 5, and 6, in patients with compensated and decompensated cirrhosis, HIV/HCV coinfection, and those who have failed previous Peg-IFN and RBV plus telaprevir or boceprevir (see trial descriptions in clinicaltrials.org). A regimen such as this could minimize total testing requirements for treatment and management (see Table 3 ).
Although HIV coinfection accelerates liver disease progression in persons with HCV infection, drug development and access to treatment have lagged behind for persons with HIV/HCV coinfection even though preliminary data from clinical trials of DAA-based treatment show very similar SVR rates to those in HCV monoinfected persons (Rockstroh and Bhagani, 2013) . Established HIV treatment programs in LMICs offer an opportunity to deliver care and treatment to coinfected individuals, leveraging the existing work force and laboratory monitoring platforms.
Monitoring treatment and ensuring adherence
It is anticipated that future treatment regimens for HCV infection will be 12 or fewer weeks in duration. Integrated programs should follow models such as one developed by the WHO for their Stop TB campaign, which addresses diagnostic needs, access to medications, adherence support, and protection of human rights (http://www.who.int/tb/strategy/stop_tb_strategy/en/). Once access to hepatitis C treatment is established, the likely real-world limitations to SVR rates over 90% will be maintaining supply chain and individual adherence rates. Adherence interventions such as directly-observed therapy or electronic reminders could be considered for regimens that take 12 or fewer weeks to complete, particularly with fixed-dose combinations and single-tablet regimens. Models to expand the pool of qualified providers in regions with inadequate numbers of HCV specialists can emulate training and expansion projects for HIV or TB care. It would be in the best interest of institutions that are funding treatment to invest in additional adherence and support programs such as peer support, directly observed therapy, text reminders, home visits, or electronically monitored pill administration or blister packaging to maximize the benefit of this fixed-duration treatment. See Table 4 for a summary of specific actions that can be taken by public and private organizations to improve the diagnosis and treatment of people living with HCV infection.
Conclusion
Low-and middle-income countries, which carry the global burden of HCV disease, should not be abandoned as high-income countries enter a new era of highly effective, all-oral, shorter duration, yet very expensive therapy for the cure of HCV infection. World-wide pressure helped create the regulatory and pricing changes that allowed millions to access life-saving HIV treatment, even though this required a commitment to life-long treatment. We need the same level of advocacy to reduce the number of premature deaths from HCV-associated complications in all countries, and short-duration treatment that can result in cure of hepatitis C infection should make this goal even more achievable than worldwide control of HIV infection. However, only providing access to more affordable medications is not enough. As stated in the WHO HCV Guidelines, ''The opportunity to address the massive HCV pandemic is now within reach and a global movement is needed to create generalized access to HCV treatment in high-, middle-and low-income countries. This will require political will, financial investment, and support from pharmaceutical, medical and civil society organizations around the world''.
We are beginning to see the broad outlines of what this global movement could look like and we hope that one day these approaches to hepatitis C will be held as models for future global health efforts. drugs. Clin. Infect. Dis. 57 (Suppl. 2), S46-S50. Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., 2010. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2), 513-521, 521 e511-e516. Table 4 Action plan to improve hepatitis C care in low-and middle-income countries. Summary of specific actions that can be taken by public and private organizations to improve the diagnosis and treatment of people living with HCV infection. Many of these have been successful in HIV or tuberculosis programs in LMIC and can be adapted to improve access to care for persons living with hepatitis C infection.
Diagnostic companies to develop anti-HCV antibody assays that are rapid, point-of-care, and cost less than US$1 and point-of-care HCV RNA assays or HCV core antigen tests that have a minimal acceptable viral detection threshold and cost less than US$10
National and Global agency funding to perform population-level anti-HCV and HCV RNA surveillance in regions with limited data Global agency support to determine the country-level burden of advanced liver disease attributable to HCV infection as well as direct and indirect costs associated with infection Academic partnerships to develop country-specific models to estimate lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios of different screening and treatment strategies as well as compared with no action National ministries of health to define a threshold for interventions to be cost effective/affordable in individual countries Countries to use TRIPS flexibilities to overcome patent barriers; these include compulsory licensing and parallel imports and patent oppositions Partnerships with pharmaceutical companies that support equitable pricing strategies through voluntary licenses that are transparent and do not have any restrictions limiting access in MICs; agreements to allow production of affordable generics; addition of patents to the Medicines Patent Pool
The World Health Organization should institute a prequalification program for HCV diagnostics, biosimilars and DAAs (which should be added to the Essential Medicines List) Provide on-line training modules and telehealth support to expand the pool of effective HCV treaters Use best practices from antiretroviral roll-out programs in HIV to provide adherence and adverse event management support, including peer support and other low cost community based adherence interventions
